Global Proliferative Diabetic Retinopathy (PDR) Therapeutics Pipeline Report, H1 2017 - Review of 8 Companies & Drug Profiles - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2017" report to their offering.

Pharmaceutical and Healthcare latest pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 3, 1 and 6 respectively.

Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

1. Introduction
2. Report Coverage
3. Proliferative Diabetic Retinopathy (PDR) - Overview
4. Proliferative Diabetic Retinopathy (PDR) - Therapeutics Development
5. Pipeline Overview
6. Pipeline by Companies
7. Products under Development by Companies
8. Proliferative Diabetic Retinopathy (PDR) - Therapeutics Assessment
9. Assessment by Target
10. Assessment by Mechanism of Action
11. Assessment by Route of Administration
12. Assessment by Molecule Type
13. Proliferative Diabetic Retinopathy (PDR) - Companies Involved in Therapeutics Development

• Acucela Inc
• Aerie Pharmaceuticals Inc
• Antisense Therapeutics Ltd
• Icon Bioscience Inc
• Ohr Pharmaceutical Inc
• PanOptica Inc
• Ribomic Inc
• ThromboGenics NV
  

For more information about this report visit http://www.researchandmarkets.com/research/ktxhwk/proliferative